The therapeutic use of psychedelics continues to gain ground in psychiatry, particularly in the management of complex disorders such as treatment-resistant depression, where available options remain l...
More than 90% of people with Down syndrome will develop symptoms of Alzheimer’s disease during their lifetime. And when epilepsy is added to that diagnosis, decline accelerates significantly. The LE...
What has long been interpreted as permanent and irreversible vascular damage may not be exclusively so. In people with Down syndrome—one of the most robust populations for studying Alzheimer’s dis...
Tauopathies, a group of neurodegenerative diseases that includes progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD), remain one of the major diagnostic challenges in neurology to...
In acute myeloid leukemia, one of the main challenges is preventing relapse: although many patients respond to the initial treatment, leukemic stem cells capable of reactivating the disease may persis...
